Vaxxinity Inc. is a biotechnology company pioneering a new class of immunotherapeutic vaccines to democratize health. Vaxxinity Inc. is based in DALLAS, Texas.
Revenue (Most Recent Fiscal Year) | $0.07M |
Net Income (Most Recent Fiscal Year) | $-56.93M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.25 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -192.58% |
Return on Assets (Trailing 12 Months) | -88.04% |
Current Ratio (Most Recent Fiscal Quarter) | 1.89 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.89 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.99 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.11 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.09 |
Earnings per Share (Most Recent Fiscal Year) | $-0.45 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.45 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 126.75M |
Free Float | 51.88M |
Market Capitalization | $16.81M |
Average Volume (Last 20 Days) | 0.95M |
Beta (Past 60 Months) | 2.39 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 59.07% |
Percentage Held By Institutions (Latest 13F Reports) | 82.95% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |